These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16048265)

  • 1. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients.
    Zoccali C; Enia G; Tripepi G; Panuccio V; Mallamaci F
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S84-7. PubMed ID: 16048265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.
    Uzun H; Konukoglu D; Besler M; Erdenen F; Sezgin C; Muderrisoglu C
    Clin Invest Med; 2008; 31(1):E1-7. PubMed ID: 18312743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular risk factor profiles among end-stage renal failure patients treated with continuous ambulatory peritoneal dialysis and intermittent hemodialysis.
    Zamiah SAKS; Draman CR; Seman MR; Safhan AF; Rozalina R; Nik Ruzni NI
    Saudi J Kidney Dis Transpl; 2018; 29(1):114-119. PubMed ID: 29456216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
    Tripepi G; Mattace Raso F; Sijbrands E; Seck MS; Maas R; Boger R; Witteman J; Rapisarda F; Malatino L; Mallamaci F; Zoccali C
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1714-21. PubMed ID: 21642364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis.
    Paniagua R; Frías Y; de Ventura MJ; Rodríguez E; Hurtado ME; Alcántara G; Vázquez R; Ortiz R; Salcedo M; Rios ME; Kaji J; Amato D
    Perit Dial Int; 2003; 23(2):132-7. PubMed ID: 12713079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients.
    Tonbul HZ; Demir M; Altintepe L; Güney I; Yeter E; Türk S; Yeksan M; Yildiz A
    Ren Fail; 2006; 28(4):287-94. PubMed ID: 16771243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients.
    Wang AY; Lam CW; Wang M; Woo J; Chan IH; Lui SF; Sanderson JE; Li PK
    Am J Kidney Dis; 2005 Apr; 45(4):715-29. PubMed ID: 15806475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
    Mallamaci F; Tripepi G; Maas R; Malatino L; Böger R; Zoccali C
    J Am Soc Nephrol; 2004 Feb; 15(2):435-41. PubMed ID: 14747391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein-energy wasting and asymmetric dimethylarginine in peritoneal dialysis patients.
    Małgorzewicz S; Heleniak Z; Lichodziejewska-Niemierko M; Rutkowski R; Aleksandrowicz-Wrona E; Dębska-Ślizień A
    Acta Biochim Pol; 2018 Dec; 65(4):581-584. PubMed ID: 30508418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients.
    Ohkuma T; Minagawa T; Takada N; Ohno M; Oda H; Ohashi H
    Am J Kidney Dis; 2003 Aug; 42(2):355-61. PubMed ID: 12900819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of serum omentin-1 level with clinical features and major adverse cardiac and cerebral events in patients undergoing continuous ambulatory peritoneal dialysis.
    Yao C; Ou J; Zhou L; Liu J
    Scand J Clin Lab Invest; 2023 Apr; 83(2):119-124. PubMed ID: 36847753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of depression with markers of nutrition and inflammation in chronic kidney disease and end-stage renal disease.
    Kalender B; Ozdemir AC; Koroglu G
    Nephron Clin Pract; 2006; 102(3-4):c115-21. PubMed ID: 16282695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen and calcium x phosphate product are predictors of cardiovascular events in the CAPD population.
    Enia G; Panuccio V; Mallamaci F; Tripepi G; Mandalari A; Zoccali C
    J Nephrol; 2005; 18(6):764-9. PubMed ID: 16358236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New markers of accelerated atherosclerosis in end-stage renal disease.
    Rattazzi M; Puato M; Faggin E; Bertipaglia B; Grego F; Pauletto P
    J Nephrol; 2003; 16(1):11-20. PubMed ID: 12649530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
    Testa A; Spoto B; Tripepi G; Mallamaci F; Malatino L; Fatuzzo P; Maas R; Boeger R; Zoccali C
    J Hypertens; 2005 Oct; 23(10):1825-30. PubMed ID: 16148605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.